Search the Newsreel

Price to earnings forward of Gilat Telecom Global Ltd – TASE:GLTL

Projeções de Resultados: Agilent Technologies Inc (A) — LPA e Crescimento de Receita

Agilon Health Earnings Call Signals Profitable Turnaround

Agilon Health's Q2 earnings call revealed a significant financial turnaround with revenue up 7.1% year-over-year to $1.5 billion and medical margin swinging from a loss to a positive $197 million. The company raised its full-year 2026 revenue guidance to $5.8 billion and adjusted EBITDA …

GILD- An Attractive Biotech Stock with Solid Base Revenue Growth

Gilead Sciences Inc. (GILD) just reported June quarter revenue up 10.2% from last year to $7.8 billion, ahead of estimates. Due to an $11.2 billion one-time write-off of acquired in-process R&D, they reported a $6.75 per share pro forma loss. But that was smaller …

Gildan Investor News: If You Have Suffered Losses in Gildan Activewear Inc. (NYSE: GIL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Gildan Activewear Inc. (NYSE: GIL) shareholders due to allegations of materially misleading business information. This investigation follows a short seller report from Jehoshaphat Research, which questioned Gildan's organic growth and sales practices, …

agilon Health (AGL) Could Be 22% Overvalued On Its Profit Turn And Outlook Raise

agilon health (AGL) reported strong Q2 results, shifting from a net loss to profit and raising its full-year 2026 revenue guidance. Despite a significant recent share price rebound, Simply Wall St's analysis suggests the stock might be 22.2% overvalued at $95.51 compared to a …

Gilead Sciences, Inc. Revenue Breakdown – SIX:GILD

Gilead Sciences, Inc. generated 23.34 billion CHF in revenue last year. Its top-performing segment, Human Immunodeficiency Virus, contributed 16.45 billion CHF, a decrease from the previous year. The United States was the largest regional contributor, accounting for 16.55 billion CHF.

Will Strong Q1 Results and Higher Guidance Change Agilysys' (AGYS) Operating Leverage Narrative?

Agilysys, Inc. reported strong first-quarter 2026 results with higher revenue and net income, alongside raised fiscal 2027 revenue and subscription growth guidance, indicating increased operating leverage in its hospitality software model. This performance supports the company's long-term thesis of a shift to cloud and …

Gildan Activewear Stock And 2 Apparel Names Shaped By New US Tariffs

Gilat Satellite Networks Q2 Earnings Call Highlights

Gilat Satellite Networks reported strong Q2 performance with a 17% year-over-year revenue increase to $122.7 million, driven by growth across commercial, defense, and Peru operations. The company also saw adjusted EBITDA rise 31% and reiterated its full-year outlook. Key highlights include significant orders for …

TD Cowen Maintains Agilon Health(AGL.US) With Hold Rating, Raises Target Price to $95

TD Cowen has reiterated its Hold rating on Agilon Health (AGL.US) and increased its target price to $95. This indicates a continued neutral stance on the stock with a slightly more optimistic outlook on its valuation.

PensionDanmark Pensionsforsikringsaktieselskab Increases Stake in Agilent Technologies, Inc. $A

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Agilent Technologies, Inc. by 9.6% during the second quarter, adding 7,371 shares to its holdings, now valued at approximately $11.1 million. Analysts maintain a "Moderate Buy" rating with a consensus target price of $159.35. Agilent Technologies exceeded quarterly …

Lazard Asset Management LLC Lowers Stock Holdings in Gilat Satellite Networks Ltd. $GILT

Noticias de acciones de Gilead Sciences Inc (GILD)

Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors?

Gilead Sciences recently reported a significant net loss of US$10.50 billion in Q2 2026, alongside cutting its full-year earnings outlook despite higher revenue. This shift to a projected full-year loss raises questions about how the company will balance investment, capital returns, and future financing, …

Agilysys CEO Ramesh Srinivasan sells $21.3m in company stock

Agilysys CEO Ramesh Srinivasan sold 197,410 shares of company stock between August 5 and August 7, 2026, totaling approximately $21.3 million. Following these transactions, Srinivasan directly holds 610,044 shares and indirectly holds 60,000 shares. This comes after Agilysys reported strong fiscal first-quarter results for …

Gilead Sciences Inc (GILD) Aktuelle Aktien-News

Agilysys, Inc. (NASDAQ:AGYS) Receives Consensus Rating of "Moderate Buy" from Analysts

Agilysys, Inc. (NASDAQ:AGYS) has received a "Moderate Buy" consensus rating from eight research firms, with an average 12-month price target of $123.60, indicating potential upside from its current price. The company recently exceeded Q1 earnings and revenue expectations, though insiders have sold a significant …

Gildan Activewear, Inc. (NYSE:GIL) Given Average Rating of "Moderate Buy" by Brokerages

Gildan Activewear, Inc. (NYSE:GIL) has received an average "Moderate Buy" rating from brokerages, with 13 out of 16 analysts recommending a buy and three suggesting a hold. The average 12-month price target is $79.07. The company recently reported strong quarterly earnings of $1.28 per …

Agilysys Inc (AGYS) Stock News Today

This article provides current stock information for Agilysys Inc (AGYS), including its market cap, P/E ratio, and recent stock performance. It notes that more news is expected soon regarding earnings, analyst ratings, and key developments for the company.

Agilon Health (AGL) Stock Price Drops Despite Sharp Margin Rebound

Agilon Health (AGL) experienced a significant stock price drop despite reporting a sharp rebound in medical margin and returning to profitability in Q2 2026. The company posted US$1.5 billion in revenue and achieved a medical margin of US$197 million, along with US$70 million in …

Agilysys (NASDAQ: AGYS) holder files to sell 25,000 shares under Form 144

Ramesh Srinivasan and Sujatha Srinivasan, joint tenants, have filed a Form 144 to sell up to 25,000 shares of Agilysys (AGYS) common stock through Morgan Stanley Smith Barney LLC on August 7, 2026. These shares originated from restricted stock that vested on June 10, …

Agilysys (AGYS) CEO sells 197,410 shares in multi-day stock sales

Agilysys (AGYS) CEO Ramesh Srinivasan sold a total of 197,410 common shares in open market or private transactions between August 5 and August 7, 2026. The sales were executed

CEO equity awards at Agilysys Inc (AGYS) tied to $105–$135 stock goals

Agilysys Inc. has granted its President & CEO, Ramesh Srinivasan, 78,270 Restricted Stock Units (RSUs) in two equal awards on June 18, 2026. One portion of 39,135 units is time-based, vesting from June 2028, while the other 39,135 units are performance-based, vesting only if …

Agilent Technologies, Inc. (NYSE:A) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Agilent Technologies, Inc. (NYSE:A) has received a "Moderate Buy" consensus rating from 19 brokerages, with an average 12-month price target of $159.35, exceeding its current share price. The company recently surpassed quarterly earnings expectations with $1.49 EPS and $1.83 billion in revenue, representing a …

Notícias das Ações da Gilead Sciences Inc (GILD)

Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead

Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration …

Gildan Activewear Inc. (GIL.TO) stock price, news, quote and history

Can agilon health (AGL) Justify Its Valuation As Earnings Turned Profitable?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why agilon health stock is in focus after the latest earnings agilon health (AGL) is back on investors' radar after second quarter results showed a shift from …

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences, Inc. GILD used its second-quarter 2026 call to emphasize stronger base-business growth, led by HIV, PrEP, Trodelvy and Livdelzi, while outlining a busy second-half launch calendar. Non-GAAP loss per share was $6.75, better than the Zacks Consensus Estimate for a loss of …

Gillanders Arbuthnot Q1 Results: Net profit turns positive to ₹353.87 lakh

agilon health, inc. Stock 12‑Month Price Target Raised to $106.69, Implies 1% Downside

agilon health, inc.'s average stock price target has been raised from $85.92 to $106.69 by 13 analysts, with a range of $31 to $141 per share. This updated target suggests a 1% potential downside based on the August 5th closing price. The consensus rating …

Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD

The Czech National Bank increased its stake in Gilead Sciences (NASDAQ:GILD) by 4.6% in Q2, bringing its total holdings to 353,398 shares valued at $44.6 million. Gilead Sciences reported Q2 revenue of $7.8 billion, exceeding analyst expectations, despite a reported loss due to acquisition …

agilon health, inc. (AGL) stock price, news, quote and history

This page provides comprehensive information on agilon health, inc. (AGL) stock, including its current price, historical data, news, and financial analysis. It details key statistics like market cap, PE ratio, and earnings date, alongside performance comparisons with the S&P 500. The article also includes …

Agilent Technologies Inc. stock outperforms competitors on strong trading day

Agilent Technologies Inc. stock (A) saw a significant rise of 3.28% to $145.97 on Friday, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average. This marked the third consecutive day of gains for the stock. The positive performance occurred …

PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% in the second quarter, acquiring an additional 25,515 shares and bringing their total holdings to 233,799 shares valued at $29.54 million. This article details various institutional investor activities, recent positive and negative …